Bd receives emergency use authorization for asymptomatic screening for sars-cov-2 through serial rapid antigen testing

Franklin lakes, n.j., april 1, 2021 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced the u.s. food and drug administration (fda) has granted emergency use authorization (eua) for its rapid antigen test to be used for sars-cov-2 screening through serial testing of asymptomatic individuals.
BDX Ratings Summary
BDX Quant Ranking